AstraZeneca plc (AZN) PT Set at GBX 4,000 by Goldman Sachs Group Inc.
AstraZeneca plc (LON:AZN) has been assigned a GBX 4,000 ($48.75) price objective by stock analysts at Goldman Sachs Group Inc. in a research report issued on Wednesday. The firm currently has a a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price target would suggest a potential downside of 20.03% from the company’s current price.
Several other research firms also recently issued reports on AZN. Citigroup Inc. reissued a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,600 ($68.25) price target on shares of AstraZeneca plc in a research note on Friday, June 24th. Societe Generale reissued a “buy” rating and issued a GBX 6,900 ($84.10) price target on shares of AstraZeneca plc in a research note on Friday, June 24th. Finally, Independent Research GmbH set a GBX 3,650 ($44.49) price target on AstraZeneca plc and gave the company a “sell” rating in a research note on Friday, June 24th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of GBX 4,960.13 ($60.45).
Shares of AstraZeneca plc (LON:AZN) opened at 4940.50 on Wednesday. The company’s 50-day moving average price is GBX 4,996.12 and its 200 day moving average price is GBX 4,492.93. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The company’s market cap is GBX 62.50 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/astrazeneca-plc-azn-pt-set-at-gbx-4000-by-goldman-sachs-group-inc.html
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.